Table 2 Mean changes in BCVA (a) and CST (b) from baseline to week 16 in the TOFU study.

From: Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

Visit

Arm 1 (N = 28)

Arm 2 (N = 28)

Arm 3 (N = 27)

(a) Mean change in BCVA

 BL

LS Mean (SE)

60.5 (2.43)

66.7 (2.43)

62.6 (2.47)

 W16

LS Mean (SE)

53.9 (3.32)

65.1 (2.79)

65.0 (2.90)

LS Mean Change from BL (SE)

−4.8 (2.17)

−1.2 (1.82)

2.2 (1.86)

p-value

0.016

0.188

 

(b) Mean change in CST

 BL

LS Mean (SE)

451.0 (24.83)

398.0 (24.83)

446.3 (25.28)

 W16

LS Mean (SE)

486.0 (29.58)

395.1 (24.81)

409.1 (25.79)

LS Mean Change from BL (SE)

37.1 (15.18)

−6.1 (12.75)

−19.4 (13.15)

p-value

0.006

0.472